Cargando…
Interleukin-13 Receptor Alpha 2-Targeted Glioblastoma Immunotherapy
Glioblastoma (GBM) is the most lethal primary brain tumor, and despite several refinements in its multimodal management, generally has very poor prognosis. Targeted immunotherapy is an emerging field of research that shows great promise in the treatment of GBM. One of the most extensively studied ta...
Autores principales: | Sengupta, Sadhak, Thaci, Bart, Crawford, Andrew C., Sampath, Prakash |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4163479/ https://www.ncbi.nlm.nih.gov/pubmed/25247196 http://dx.doi.org/10.1155/2014/952128 |
Ejemplares similares
-
Enhanced Transduction and Replication of RGD-Fiber Modified Adenovirus in Primary T Cells
por: Sengupta, Sadhak, et al.
Publicado: (2011) -
Impact of Temozolomide on Immune Response during Malignant Glioma Chemotherapy
por: Sengupta, Sadhak, et al.
Publicado: (2012) -
Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme
por: Newman, Jennifer P., et al.
Publicado: (2017) -
Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers
por: Liang, Ruijia, et al.
Publicado: (2022) -
Generation of interleukin-13 receptor alpha2 antigen expressing modified vaccinia ankara recombinant virus for potential cancer immunotherapy
por: Sato, Yuki, et al.
Publicado: (2014)